Literature DB >> 1651964

Elevated endogenous digitalis-like substance in hypertensive diabetic patients with a family history of hypertension.

S Okamoto1, M Ikeda, T Morise, I Miyamori, R Takeda.   

Abstract

Endogenous digital-like substance (DLS) is increased in patients with essential hypertension and is hypothesized to play a role in the pathogenesis of high blood pressure. Whether an increase in DLS in diabetic patients with hypertension is associated with a family history of hypertension or diabetic nephropathy was investigated. Plasma DLS was measured as Na(+)-K(+)-ATPase inhibitory activity (ATPI) in 100 Type 2 diabetic patients. Ouabain was used as a standard of Na-K-ATPase inhibition. Diabetic patients with hypertension demonstrated a greater ATPI level than normotensive diabetic patients (p less than 0.05). In patients with hypertension groups, the positive family history group had a higher ATPI level than the negative family history group (p less than 0.01). Microalbuminuria was not correlated with the ATPI level in diabetic patients. These results suggest that ATPI might play a role in the pathogenesis of hereditary hypertension associated with diabetes mellitus, but not have etiologic significance in diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651964     DOI: 10.1007/BF03349083

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Rapid large-scale isolation of biologically active molecules using reversed-phase "flash" chromatography: initial purification of endogenous Na+, K+-ATPase inhibitors from human urine.

Authors:  I W Wainer; M Crabos; J F Cloix
Journal:  J Chromatogr       Date:  1985-03-22

Review 2.  Cellular sodium transport in essential hypertension.

Authors:  P J Hilton
Journal:  N Engl J Med       Date:  1986-01-23       Impact factor: 91.245

3.  Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus.

Authors:  A S Krolewski; M Canessa; J H Warram; L M Laffel; A R Christlieb; W C Knowler; L I Rand
Journal:  N Engl J Med       Date:  1988-01-21       Impact factor: 91.245

Review 4.  Microalbuminuria as a predictor of clinical diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Kidney Int       Date:  1987-02       Impact factor: 10.612

5.  The heterogeneity of essential hypertension. Relation between lithium efflux and sodium content of erythrocytes and a family history of hypertension.

Authors:  G Clegg; D B Morgan; C Davidson
Journal:  Lancet       Date:  1982-10-23       Impact factor: 79.321

6.  Partial purification and properties of the inhibitors of Na, K-ATPase and ouabain-binding in bovine central nervous system.

Authors:  K Akagawa; N Hara; Y Tsukada
Journal:  J Neurochem       Date:  1984-03       Impact factor: 5.372

7.  Inherited defect in a Na+, K-co-transport system in erythrocytes from essential hypertensive patients.

Authors:  R P Garay; G Dagher; M G Pernollet; M A Devynck; P Meyer
Journal:  Nature       Date:  1980-03-20       Impact factor: 49.962

8.  Sodium-lithium countertransport in erythrocytes of hypertension prone families in Utah.

Authors:  R R Williams; S C Hunt; H Kuida; J B Smith; K O Ash
Journal:  Am J Epidemiol       Date:  1983-09       Impact factor: 4.897

9.  Radioactive 86rubidium influx into red blood cells in essential hypertension in relation to the plasma renin activity.

Authors:  K Horký; V Schreiber; T Pribyl
Journal:  Horm Metab Res       Date:  1984-01       Impact factor: 2.936

10.  [Endogenous digitalis-like substance and Na-K-ATPase inhibitor in cardiovascular and renal disease].

Authors:  S Okamoto
Journal:  Nihon Naibunpi Gakkai Zasshi       Date:  1988-01-20
View more
  1 in total

Review 1.  Endogenous factors with immunological and biological activity similar to cardiac glycosides: biochemical and pathophysiological implications.

Authors:  A Clerico; G Mariani
Journal:  J Endocrinol Invest       Date:  1992-05       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.